The company said, “As announced in February 2024, the U.S. Food and Drug Administration issued a Complete Response Letter to our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia. Interactions with the FDA continue with the goal of addressing questions raised in the CRL.” Cash Position: Cash, cash equivalents and restricted cash at September 30, 2024 were approximately $26.6 million, as compared to $41.0 million at December 31, 2023.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NERV: